Clinical Core and Data Coordination Center

丙型肝炎病毒是一个重大的公共卫生问题，其临床结果是可变的。宿主病毒相互作用 在疾病和治疗结果中发挥重要作用，但潜在的免疫机制 导致自发或与治疗相关的病毒清除的原因尚不清楚。这些研究 在此丙型肝炎合作研究中心(HC CRC)内提出的应用重点是 丙型肝炎病毒控制的先天免疫机制。所有三个项目中的拟议研究都包括这两项 慢性丙型肝炎患者临床标本的体外翻译研究 评估丙型肝炎病毒天然免疫触发、反应和感染控制机制的费用。 这些研究将依赖于专门的人类肝组织、血清、血浆样本和相关的临床研究。 信息。因此，我们建议建立一个临床核心，为本中心所有三个项目提供服务 哈佛医学院贝丝以色列女执事医疗中心(BIDMC)的肝脏中心是一个 波士顿地区的主要第三转诊中心，将能够满足临床的要求 核心。临床核心将成为U19计划全球研究的中心平台，通过 提供临床专业知识和有特色的临床标本，以支持对 在这个HC CRC的每个单独项目中的假设。

Hepatitis C virus is a significant public health issue and its clinical outcomes are variable. Host virus interactions play important roles in disease and treatment outcomes but the underlying Immunological mechanisms leading to spontaneous or treatment associated viral clearance are not welt understood. The studies proposed within this Hepatitis C Cooperative Research Center (HC CRC) application are focused on the innate immune mechanisms of HCV control. The proposed studies within all three projects Include both translational investigation using clinical specimens from patients with chronic hepatitis C, and in vitro expenments to evaluate mechanisms of HCV innate immune triggering, response, and infection control. These studies will rely on specialized human liver tissues, sera, plasma samples, and the associated clinical Information. Thus, we propose to establish a Clinical Core for service to all three projects in this HC CRC Program, The Liver Center at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, is a major tertiary referral center in the Boston region and will be able to meet the requirements of the Clinical Core. The Clinical Core will serve as a central platform for the global studies in the U19 Program by providing clinical expertise and well characterized clinical specimens in support of investigating the hypotheses within each individual project of this HC CRC.